A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations | Zendy

Sai Prasad Desikan | Zendy; Farhad Ravandi | Zendy; Naveen Pemmaraju | Zendy; Marina Konopleva | Zendy; Sanam Loghavi | Zendy; Elias Jabbour | Zendy; Naval Daver | Zendy; Nitin Jain | Zendy; Kelly S. Chien | Zendy; Abhishek Maiti | Zendy; Guillermo MontalbanBravo | Zendy; Tapan M. Kadia | Zendy; Walid Macaron | Zendy; Ricardo Delumpa | Zendy; Monica Kwari | Zendy; Gautam Borthakur | Zendy; Nicholas J. Short | Zendy

Open Access

A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations

Author(s) -

Sai Prasad Desikan,

Farhad Ravandi,

Naveen Pemmaraju,

Marina Konopleva,

Sanam Loghavi,

Elias Jabbour,

Naval Daver,

Nitin Jain,

Kelly S. Chien,

Abhishek Maiti,

Guillermo MontalbanBravo,

Tapan M. Kadia,

Walid Macaron,

Ricardo Delumpa,

Monica Kwari,

Gautam Borthakur,

Nicholas J. Short

Publication year - 2022

Publication title -

acta haematologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.574

H-Index - 56

eISSN - 1421-9662

pISSN - 0001-5792

DOI - 10.1159/000525566

Subject(s) - venetoclax , azacitidine , trametinib , medicine , myeloid leukemia , oncology , adverse effect , leukemia , biology , mapk/erk pathway , biochemistry , gene expression , chronic lymphocytic leukemia , kinase , dna methylation , gene , microbiology and biotechnology

RAS pathway mutations are common mechanisms of resistance to acute myeloid leukemia (AML) therapies. Trametinib, an oral MEK inhibitor, has been shown to have single-agent activity in relapsed/refractory AML and preclinical synergy with venetoclax.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research